Literature DB >> 2208580

Phase I trial of indicine-N-oxide in children with leukemia and solid tumors: a Pediatric Oncology Group study.

V M Whitehead1, M L Bernstein, R Vega, T Vats, P Dyment, T J Vietti, J Krischer.   

Abstract

A phase I trial of indicine-N-oxide was carried out in 12 children with solid tumors and in 16 with leukemia. Doses of 5, 6, and 7.5 g/m2 were given parenterally as a 15-min infusion every 3 weeks. The maximum tolerated dose in patients with solid tumors was 7.5 g/m2 and the dose-limiting toxicity was myelosuppression. In leukemia, the maximum tolerated dose was 6.0 g/m2 and hepatotoxicity was dose-limiting. Half of the children with leukemia showed elevations in transaminase levels and one child died of massive hepatic necrosis. This hepatotoxicity limits the use of indicine-N-oxide in children with leukemia. Antineoplastic activity was limited to a transient reduction in the numbers of circulating leukemic cells.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2208580     DOI： 10.1007/bf02897298

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


  11 in total

1.  High incidence of veno-occlusive disease related to indicine N-oxide in the treatment of refractory adult acute leukemia.

Authors:  E F Winton; P A McCue
Journal:  Cancer Treat Rep       Date:  1986-07

Review 2.  Indicine N-oxide: clinical use of a pyrrolizidine alkaloid.

Authors:  S A King; M Suffness; B Leyland-Jones; D F Hoth; P J O'Dwyer
Journal:  Cancer Treat Rep       Date:  1987-05

3.  Disposition of indicine N-oxide in mice and monkeys.

Authors:  S M El Dareer; K F Tillery; H H Lloyd; D L Hill
Journal:  Cancer Treat Rep       Date:  1982-01

4.  Toxicity and pharmacokinetics of a pyrrolizidine alkaloid, indicine N-oxide, in humans.

Authors:  J S Kovach; M M Ames; G Powis; C G Moertel; R G Hahn; E T Creagan
Journal:  Cancer Res       Date:  1979-11       Impact factor: 12.701

5.  Veno-occlusive disease of the liver following high-dose chemotherapy and autologous bone marrow transplantation in children with solid tumors: incidence, clinical course and outcome.

Authors:  L Brugieres; O Hartmann; E Benhamou; E S Zafrani; J M Caillaud; C Patte; C Kalifa; F Flamant; J Lemerle
Journal:  Bone Marrow Transplant       Date:  1988-01       Impact factor: 5.483

6.  Hepatic failure secondary to indicine N-oxide toxicity. A Pediatric Oncology Group Study.

Authors:  B A Cook; J R Sinnhuber; P J Thomas; T A Olson; T A Silverman; R Jones; V M Whitehead; F B Ruymann
Journal:  Cancer       Date:  1983-07-01       Impact factor: 6.860

7.  Phase I study of indicine N-oxide in patients with advanced cancer.

Authors:  T Ohnuma; K S Sridhar; L H Ratner; J F Holland
Journal:  Cancer Treat Rep       Date:  1982-07

8.  Venocclusive disease of the liver after allogeneic bone marrow transplantation in man.

Authors:  G Ganem; M F Saint-Marc Girardin; M Kuentz; C Cordonnier; G Marinello; C Teboul; F Braconnier; J P Vernant; D Dhumeaux; J P Le Bourgeois
Journal:  Int J Radiat Oncol Biol Phys       Date:  1988-05       Impact factor: 7.038

9.  Activity of indicine N-oxide in refractory acute leukemia.

Authors:  L Letendre; W A Smithson; G S Gilchrist; E O Burgert; C H Hoagland; M M Ames; G Powis; J S Kovach
Journal:  Cancer       Date:  1981-02-01       Impact factor: 6.860

10.  Hepatocellular toxicity during the treatment of refractory acute leukemia with indicine N-oxide.

Authors:  L Letendre; J Ludwig; J Perrault; W A Smithson; J S Kovach
Journal:  Cancer       Date:  1984-10-01       Impact factor: 6.860
View more
  1 in total

1.  Phase I and Phase II Objective Response Rates are Correlated in Pediatric Cancer Trials: An Argument for Better Clinical Trial Efficiency.

Authors:  Jonathan C Yeh; Peng Huang; Kenneth J Cohen
Journal:  J Pediatr Hematol Oncol       Date:  2016-07       Impact factor: 1.289
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.